Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIONEER-PEDS1 lasmiditan study in children and adolescents with migraine
NL-OMON58723Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of lasmiditan in migraine, sponsored by Eli Lilly and Company. Primary endpoint: Percentage of participants with pain freedom (high dose). Started Apr 2021; status: completed.
02
Drugs
lasmiditan
03
Conditions
migraine
Beyond the preview
Go deeper on NL-OMON58723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58723.